Skip to content
sellWeak

Weiguo Ye sold $69k of GYRE

Chief Operating Officer at GYRE THERAPEUTICS, INC.. 11,000 shares at an average of $6.25, traded Jun 9, 2026, filed Jun 22, 2026.

Warning score
13
Value
$69k
11,000 shares
Holdings after
700,000
-2% from before
From 52-week low
+10%
low $5.56, close $6.13
From 52-week high
-32%
high $9.00, as of Jun 9, 2026

Score components

  • Role
    COO
    +20
  • Trade size
    $69k at market
    +8
  • Share of holdings sold
    Sold 1.6% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GYREOct 12, 2026 · close 6.87
Since filing Jun 22, 2026: +12.1%SPY +4.8% · excess +7.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001140361-26-025950, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 9, 2026MOption exercise
Common Stock
+3,000$0.75$2,250703,000Jun 22, 2026
Jun 9, 2026SOpen-market sale
Common Stock
-3,000$6.15$18k700,000Jun 22, 2026
Jun 10, 2026MOption exercise
Common Stock
+5,000$0.75$3,750705,000Jun 22, 2026
Jun 10, 2026SOpen-market sale
Common Stock
-5,000$6.24$31k700,000Jun 22, 2026
Jun 18, 2026MOption exercise
Common Stock
+3,000$0.75$2,250703,000Jun 22, 2026
Jun 18, 2026SOpen-market sale
Common Stock
-3,000$6.35$19k700,000Jun 22, 2026
Jun 9, 2026MOption exercise
Stock Option (Right to Buy)derivative
-3,000$0.00$0835,701Jun 22, 2026
Jun 10, 2026MOption exercise
Stock Option (Right to Buy)derivative
-5,000$0.00$0830,701Jun 22, 2026
Jun 18, 2026MOption exercise
Stock Option (Right to Buy)derivative
-3,000$0.00$0827,701Jun 22, 2026

Related signals

Other insiders at GYRE THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
5Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$17k
2,800 shares
-0%
16Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$129k
20,918 shares
-3%
17Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$219k
34,976 shares
-5%
11Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$46k
7,500 shares
-1%
16Weak
GYREsell
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$137k
22,220 shares
-3%
20Weak
GYREsell 2
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$59k
9,320 shares
-1%
25Weak
GYREsell 2
GYRE THERAPEUTICS, INC.
Weiguo Ye
Chief Operating Officer
$195k
28,680 shares
-4%
22Weak
GYREsell 210b5-1
GYRE THERAPEUTICS, INC.
Ying Luo
Chief Executive Officer
$83k
10,315 shares
-0%
5Weak
GYREsell10b5-1
GYRE THERAPEUTICS, INC.
Songjiang Ma
President
$26k
2,558 shares
-0%
0Weak
GYREsell10b5-1
GYRE THERAPEUTICS, INC.
Songjiang Ma
President
$24k
2,182 shares
-0%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Weiguo Ye sold $69k of GYRE | InsiderTell